Department of Analytic Human Pathology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Lab Invest. 2019 Jun;99(6):853-865. doi: 10.1038/s41374-018-0158-9. Epub 2019 Feb 6.
Although mammalian target of rapamycin inhibitors (mTORi) are used to treat various malignancies, they frequently induce active alveolitis and dyslipidemia. Abnormal lipid metabolism affects alveolar surfactant function and results in pulmonary disorders; however, the pathophysiology of lung injury and its relationship with lipid metabolism remain unknown. We investigated the relationship between lipid metabolism and alveolar epithelial injury, focusing on peroxisome proliferator-activated receptor-γ (PPAR-γ) as a lipid stress-related factor in mTORi-induced lung injury. We clinicopathologically examined three patients with mTORi-induced lung injury. We constructed an mTORi injury mouse model using temsirolimus in mice (30 mg/kg/day), with the vehicle control and bleomycin injury groups. We also constructed a cultured alveolar epithelial cell injury model using temsirolimus (0-40 μM) in the mouse lung epithelial cell line MLE-12 and performed analysis with or without pioglitazone (PPAR-γ agonist) treatment. All three patients had dyslipidemia and lung lesions of hyperplastic pneumocytes with foamy and enlarged changes. In the mouse model, temsirolimus induced significantly higher levels of total cholesterol and free fatty acids in serum and higher levels of surfactant protein D in serum and BAL fluid with an increase in inflammatory cytokines in the lung compared to control. Temsirolimus also induced hyperplastic foamy pneumocytes with increased lipid-associated spots and larger round electron-lucent bodies compared to the control or bleomycin groups in microscopic analyses. Multiple lipid-associated spots within the cytoplasm were also induced by temsirolimus administration in MLE-12 cells. Temsirolimus downregulated PPAR-γ expression in mouse lung and MLE-12 cells but upregulated cleaved caspase-3 in MLE-12 cells. Pioglitazone blocked the upregulated cleaved caspase-3 expression in MLE-12 cells. The pathogenesis of mTORi-induced lung disease may be involved in alveolar epithelial injury, via lipid metabolic stress associated with downregulated PPAR-γ expression. Focusing on the relationship between lipid metabolic stress and alveolar epithelial injury represents a potentially novel approach to the study of pulmonary damage.
尽管哺乳动物雷帕霉素靶蛋白抑制剂(mTORi)被用于治疗各种恶性肿瘤,但它们经常引发活跃的肺泡炎和血脂异常。异常的脂质代谢会影响肺泡表面活性剂的功能,导致肺部疾病;然而,肺损伤的病理生理学及其与脂质代谢的关系尚不清楚。我们研究了脂质代谢与肺泡上皮损伤之间的关系,重点关注过氧化物酶体增殖物激活受体-γ(PPAR-γ)作为 mTORi 诱导的肺损伤中的脂质应激相关因子。我们临床病理检查了 3 例 mTORi 诱导的肺损伤患者。我们使用西罗莫司(temsirolimus)在小鼠中构建 mTORi 损伤模型(30mg/kg/天),并设立了载体对照组和博来霉素损伤组。我们还使用 mTORi(0-40μM)在小鼠肺上皮细胞系 MLE-12 中构建了培养的肺泡上皮细胞损伤模型,并在有或没有吡格列酮(PPAR-γ 激动剂)治疗的情况下进行了分析。所有 3 名患者均有血脂异常和增生性肺泡细胞病变,伴有泡沫状和增大改变。在小鼠模型中,与对照组相比,西罗莫司诱导血清总胆固醇和游离脂肪酸水平显著升高,血清和 BAL 液中表面活性蛋白 D 水平升高,肺中炎症细胞因子增加。与对照组或博来霉素组相比,西罗莫司还诱导增生性泡沫状肺泡细胞,细胞质内的多个脂滴相关斑点和更大的圆形电子透明体增加。西罗莫司给药还在 MLE-12 细胞中诱导多个脂滴相关斑点。西罗莫司下调了小鼠肺和 MLE-12 细胞中的 PPAR-γ 表达,但上调了 MLE-12 细胞中的 cleaved caspase-3。吡格列酮阻断了 MLE-12 细胞中 cleaved caspase-3 的上调表达。mTORi 诱导的肺疾病的发病机制可能涉及肺泡上皮损伤,通过与下调的 PPAR-γ 表达相关的脂质代谢应激。关注脂质代谢应激与肺泡上皮损伤之间的关系,可能为研究肺部损伤提供一种新的方法。